PRCTPROCEPT BioRobotics Corporation
What is the market doing?
No clear lean: insiders net buying, but heavily shorted (+13% of shares).
Rangebound, no clear trend. Price is −17% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 22, 2026.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover. Level with the previous count, down from 13.4% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PRCT is trading
PROCEPT BioRobotics Corporation is −41% over the past year while the S&P 500 is +16%: 57 points behind the market. Through the fall, its own insiders bought $448K more stock than they sold.
1-year return · S&P 500 +16%
- vs 200-day average
- −17%
vs 200-day average · a clear downtrend
- RSI (14)
- 61
RSI (14) · neutral
- Below its 52-week high
- 46%
Below its 52-week high
Details›
- Last close2026-10-23
- $19.95
- 1 monthS&P 500 −0.94%
- +14%
- 1 yearS&P 500 +16%
- −41%
- 5 yearsS&P 500 +86%
- −52%
- vs 50-day average$19.58
- +1.9%
- 52-week high
- $36.95
- 52-week low
- $16.69
- Annualised volatility
- 63%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-22
- $448K
| Year | Return |
|---|---|
| 2026 (year to date) | −37% |
| 2025 | −61% |
| 2024 | +92% |
| 2023 | +0.89% |
| 2022 | +66% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 1 of 5 | −7.9% |
| Feb | 5 | 2 of 5 | +0.51% |
| Mar | 5 | 3 of 5 | +3.8% |
| Apr | 5 | 3 of 5 | +0.92% |
| May | 5 | 5 of 5 | +12% |
| Jun | 5 | 1 of 5 | −6.7% |
| Jul | 5 | 2 of 5 | −3.5% |
| Aug | 5 | 3 of 5 | +5.9% |
| Sep | 5 | 2 of 5 | −5.0% |
| Oct | 6 | 4 of 6 | +3.4% |
| Nov | 5 | 2 of 5 | +1.7% |
| Dec | 5 | 1 of 5 | −6.0% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.